Exploratory Efficacy of INP104 in Patients Using Concomitant Preventive Migraine Medications
Synopsis
Results suggest that INP104 may be an effective and well-tolerated acute therapy for migraine in patients who are concurrently using preventive therapies.
Disclosures
Jihan Grant participated in an Advisory Board meeting for Satsuma Pharmaceuticals. Robert Vann, Christopher Fitzpatrick, TinaMarie Lieu, Stephen B. Shrewsbury, and Sheena K. Aurora are full-time employees of Impel Pharmaceuticals and are stockholders in Impel Pharmaceuticals. Stephen B. Shrewsbury is an officer of Impel Pharmaceuticals.
Author(s):
- Dr. Sheena Aurora, MD, Medical Affairs, Impel Pharmaceuticals
- Jihan Grant, Neurologist, Icahn School of Medicine at Mount Sinai
- Robert Vann, Medical Affairs, Impel Pharmaceuticals
- Christopher Fitzpatrick, Medical Affairs, Impel Pharmaceuticals
- Stephen B. Shrewsbury, CMO, Impel Pharmaceuticals
| Display Label | Action |
|---|---|
| Concomitant preventives poster | Download Resource |
| IMPEL_~1 | Download Resource |